Literature DB >> 10673684

A successful cord blood transplant in a child with second accelerated phase chronic myeloid leukemia following lymphoid blast crisis.

A A Maschan1, E V Skorobogatova, E V Samotchatova, D N Balashov, M I Yourlova, N I Bogatcheva, E D Pashanov, P E Trakhtman, A M Timakov, A G Rumiantzev.   

Abstract

We describe a 5-year-old girl with Ph(+) CML who received a cord blood transplant in a second accelerated phase after a very early lymphoid blast crisis. She was induced into CR by ALL-directed chemotherapy and then maintained with IFN-alpha2b together with weekly rotational chemotherapy. Nineteen months after diagnosis, her mother gave birth to an HLA-compatible sibling, whose cord blood was cryopreserved. The patient's second acceleration occurred 22 months after the CML diagnosis. The subsequent conditioning regimen included busulfan 16 mg/kg, Ara-C 12 g/m2 and melphalan 140 mg/m2. In order to prevent GVHD, CsA alone was administered, 3 mg/kg i.v. per day for a total of 40 days. The total number of nucleated cells infused was 0.8 x 108/kg, with CD34+ cells 1.8 x 106/kg and CFU-GM 1 x 104/kg. Engraftment occurred on day +35. Respiratory distress, severe VOD and grade II acute gastrointestinal GVHD complicated the post-transplant period. No chronic GVHD occurred. The girl is alive 23 months after transplantation with complete donor chimerism; both Ph chromosome and bcr/abl RNA are negative. Bone Marrow Transplantation (2000) 25, 213-215.

Entities:  

Mesh:

Year:  2000        PMID: 10673684     DOI: 10.1038/sj.bmt.1702105

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation.

Authors:  Akiyoshi Takami; Shigeru Shimadoi; Chiharu Sugimori; Kenichi Takemoto; Masami Shibayama; Tomotaka Yoshida; Tohru Murayama; Kenichi Nagai; Koichi Miyamura; Hidesaku Asakura; Shinji Nakao
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

Review 2.  Insights and hopes in umbilical cord blood stem cell transplantations.

Authors:  Somayeh Shahrokhi; Farid Menaa; Kamran Alimoghaddam; Colin McGuckin; Massoumeh Ebtekar
Journal:  J Biomed Biotechnol       Date:  2012-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.